Nereid Therapeutics was born from discoveries and technologies developed by academic founder Clifford Brangwynne, Ph.D., a pioneer of the biomolecular condensate field and one of the world’s leading experts in intracellular liquid-liquid phase separation (LLPS).
If you’ve seen a lava lamp in motion, then you’ve seen LLPS in action. LLPS also occurs in living cells, where it underlies the formation and function of membrane-less compartments. It is increasingly understood that such membrane-less droplets inside cells play dynamic roles in gene regulation and in a host of disease processes. However, until now there has never been a way to systematically measure intracellular LLPS and determine the impact of therapeutics on the process. Enter Nereid Therapeutics.
New technologies developed by the Brangwynne laboratory and deployed by Nereid illuminate the formation and behavior of these droplets and enable the precise measurement of LLPS in mammalian cells. Combined with state-of-the-art proprietary microscopy and computer vision, Nereid scientists are using LLPS to discover small molecules that can modulate protein interactions found in disease states, in ways that have not been possible before.
Nereid marries soft matter physics to cell biology to pioneer a new way to fight intractable diseases— cancers, neurodegenerative illnesses, and inflammatory disorders, among others. Nereid starts with unparalleled approaches to see and measure the biomolecular forces driving phase separation, amplifying insights with machine learning, and accelerating translation with state-of-the-art cell biology and medicinal chemistry. Nereid’s platform charts a new path, using physics to discover therapeutics that can modify the phase behavior of living cells.
ATP is developing the next generation of transformative life sciences companies.